Kazia Therapeutics Limited (KZIA)
KZIA Stock Price Chart
Explore Kazia Therapeutics Limited interactive price chart. Choose custom timeframes to analyze KZIA price movements and trends.
KZIA Company Profile
Discover essential business fundamentals and corporate details for Kazia Therapeutics Limited (KZIA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
6 Jan 1999
Employees
9.00
CEO
John Edwin Friend II,
Description
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
KZIA Financial Timeline
Browse a chronological timeline of Kazia Therapeutics Limited corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 28 Aug 2025
EPS came in at -$0.01 matching the estimated -$0.01, while revenue for the quarter reached $10.45K , meeting expectations.
Earnings released on 28 May 2025
Stock split effective on 17 Apr 2025
Shares were split 1 : 5 , changing the number of shares outstanding and the price per share accordingly.
Stock split effective on 21 Mar 2025
Shares were split 1 : 5 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 19 Nov 2024
EPS came in at -$0.04 surpassing the estimated -$15.00 by +99.72%, while revenue for the quarter reached $1.65M , beating expectations by +1.55K%.
Stock split effective on 28 Oct 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 27 Mar 2024
EPS came in at -$0.03 , while revenue for the quarter reached $3.40 .
Earnings released on 27 Nov 2023
EPS came in at -$0.02 surpassing the estimated -$1.66 by +98.79%, while revenue for the quarter reached $368.58 .
Earnings released on 9 Mar 2023
EPS came in at -$0.06 surpassing the estimated -$24.65 by +99.74%.
Earnings released on 6 Oct 2022
EPS came in at -$0.06 surpassing the estimated -$29.93 by +99.80%, while revenue for the quarter reached -$1.99M , missing expectations by -56.70K%.
Earnings released on 6 Jan 2022
EPS came in at -$0.07 , while revenue for the quarter reached $7.25K .
Earnings released on 30 Sept 2021
EPS came in at -$0.01 surpassing the estimated -$2.30 by +99.49%, while revenue for the quarter reached $11.40M , missing expectations by -22.52%.
Earnings released on 31 Dec 2020
EPS came in at -$0.05 surpassing the estimated -$2.30 by +98.03%, while revenue for the quarter reached $897.27 , missing expectations by -99.80%.
Earnings released on 22 Oct 2020
EPS came in at -$0.05 , while revenue for the quarter reached $251.13K , missing expectations by -89.39%.
Stock split effective on 2 Oct 2020
Shares were split 1041 : 1000 , changing the number of shares outstanding and the price per share accordingly.
KZIA Stock Performance
Access detailed KZIA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.